Clinical trial · Observational
Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy
Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy Based on Tumor Subtypes in Patients With Early-stage Breast Cancer: A Multi-institutional Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adjuvant chemotherapy | Procedure | — | UNRESOLVED |
| Neoadjuvant chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Neoadjuvant chemotherapy (NACT) group
- description
- Patients who administered chemotherapy before surgery
- interventionNames
- Procedure: Neoadjuvant chemotherapy
- label
- Adjuvant chemotherapy (ACT) group
- description
- Patients who administered chemotherapy after surgery
- interventionNames
- Procedure: Adjuvant chemotherapy
Primary outcomes (1)
- measure
- Locoregional recurrence-free survival (LRR)
- timeFrame
- Defined as the time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of LRR, assessed up to 120 months
- description
- Time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of locoregional recurrence
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who underwent breast-conserving surgery for invasive breast cancer between 2004 and 2018 Exclusion Criteria: * Total mastectomy * No pre- or postoperative chemotherapy * No radiation therapy * Bilateral breast cancer * Male breast cancer patients * Secondary breast cancer * Metachronous or synchronous cancers
References
Publications (0)
Data not yet available